Podcasts about life sciences

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's guest is Mathias Cousin, Managing Director at Deloitte. With extensive experience in R&D transformation and regulated industry data strategy, Mathias joins Emerj Editorial Director Matthew DeMello to unpack what it really takes for enterprise leaders to deliver ROI from AI and data initiatives. Mathias also shares actionable guidance on building effective “string of pearls” use cases, investing in data quality and AI-native talent, and adopting practical change management to embed AI in workflows for measurable gains in efficiency and long-term competitive edge. This episode is sponsored by Deloitte. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

Investing in health and science research isn't just about curing diseases. It has huge impacts across society, from creating jobs to driving economic growth to boosting national competitiveness. Study shows that every $ invested in the life sciences industry generates $3 in GDP globally, whereas every job created in the life sciences industry generates five in the global economy. Life sciences are one of the most powerful engines of prosperity, yet many governments still underestimate their economic return.In this episode of The Ripple Effect: Investing in Life Sciences, host Dan Riskin speaks with Patrick Horber, President of Novartis International, and David Gluckman, Vice Chairman of Investment Banking and Global Head of Healthcare at Lazard. Together, they break down the outsized economic impact of life science innovation, from trillions in US bioscience output to China's meteoric rise as a global R&D hub. The conversation delves into the ways governments can support innovation with not just money, but through policy and regulation; plus, some of the best ways that countries can help the sector secure investment, talent, and long-term growth.This limited series, produced by GZERO's Blue Circle Studios in partnership with Novartis, examines how life science innovation plays a vital role in fulfilling that commitment. Host: Dan RiskinGuests: Patrick Horber, David Gluckman  Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Carla Tardiff has spent 17 years as the CEO of Family Reach, a nonprofit that shouldn't have to exist but absolutely does—because in America, cancer comes with a price tag your insurance doesn't cover.We talk about shame, fear, burnout, Wegmans, Syracuse, celebrity telethons, and the godforsaken reality of choosing between food and treatment. Carla's a lifer in this fight, holding the line between humanity and bureaucracy, between data and decency. She's also sharp as hell, deeply funny, and more purpose-driven than half of Congress on a good day.This episode is about the work no one wants to do, the stuff no one wants to say, and why staying angry might be the only way to stay sane.Come for the laughs. Stay for the rage. And find out why Family Reach is the only adult in the room.RELATED LINKSFamily ReachFinancial Resource CenterCarla on LinkedInMorgridge Foundation ProfileAuthority Magazine InterviewSyracuse University FeatureFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

For the first time in decades, a major innovation in reproductive health is on the horizon. In this episode of StartUp Health NOW, StartUp Health community member Dr. Darlene Walley, CEO of NEXT Life Sciences, joins Unity Stoakes to discuss Plan A™, a long-acting, non-hormonal, fully reversible male contraceptive that could reshape how couples share family planning. Dr. Walley explains how Plan A works as a medical device, the company's global license for Vasalgel®, and the breakthrough results from 100% successful delivery device trials across two continents. With FDA-approved development plans and growing clinical momentum, the company is on track to submit for approval by 2027. Beyond science, this conversation explores a cultural shift: how men are stepping up to share responsibility for contraception and how this innovation could expand access, improve preventive care, and strengthen relationships worldwide. Listen in for a look at the future of men's health, reproductive equity, and one of the most anticipated breakthroughs in medical innovation. Are you ready to tell YOUR story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world's biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is a benefit of our Health Moonshot PRO Membership. To schedule a call and see if you qualify to join and increase brand awareness through our multi-media storytelling efforts, submit our three-minute application. If you're mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit. » Learn more and apply today. Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.

In this episode of BioTalk with Rich Bendis, Harry Coker, Jr., Secretary of the Maryland Department of Commerce, joins the podcast to discuss Maryland's rising momentum as a global biohealth and technology leader. Secretary Coker shares his unique journey from the CIA, NSA, and White House to leading Maryland's economic development strategy, highlighting the state's strengths in life sciences, its appeal to global investors, and the importance of public-private partnerships in accelerating innovation.   Topics include Maryland's recent recognition as a Top 3 biopharma hub, the decision to prioritize Life Sciences and Computational Biology as “Lifehouse” sectors, and how the state is leveraging the BioHealth Capital Region identity to unite and expand its regional leadership. He also outlines Maryland's case for investment and why collaboration will be central to "Winning the Decade."   Editing and post-production work for this episode was provided by The Podcast Consultant.   The Honorable Harry Coker, Jr. was appointed by Governor Wes Moore as Maryland's Secretary of Commerce in 2025. He is a retired senior executive from the CIA and NSA, former National Cyber Director at the White House, and a career Naval Officer. Coker's leadership is shaped by decades of public service at the highest levels of national security and technology. At the Maryland Department of Commerce, he leads efforts to build an equitable, competitive economy centered around innovation, inclusion, and impact.

In this episode of Tiny Show and Tell Us, we get to the bottom of if glass is a liquid or a solid and why riboflavin makes milk fluorescent. Then we talk about the Laser Interferometer Space Antenna (LISA) — the first space-based observatory that NASA scientists and their collaborators are sending up into space to detect and study gravitational waves, better known as “ripples in spacetime.” We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Lab Rats to Unicorns, John Flavin is joined by Todd Manjuck—Associate on JPMorgan's Innovation Economy team and former U.S. Navy SEAL. Todd supports venture-backed companies across the life sciences sector, helping founders and executives navigate the unique challenges of scaling healthcare businesses. From capital access to operational strategy, Todd serves as a connector between early-stage innovators and the broader ecosystem. Before entering the world of finance and innovation, Todd spent over eight years as a Navy SEAL, an experience that continues to shape his approach to leadership, resilience, and decision-making under uncertainty. He reflects on how lessons from special operations translate to biotech—whether in adapting strategy, managing risk, or building strong teams. Throughout the conversation, Todd shares his perspectives on today's life sciences landscape, the parallels between entrepreneurship and combat training, and the importance of mentorship and resilience in the face of uncertainty. He also opens up about his mother's cancer journey, which inspires his commitment to supporting companies working to advance treatments and improve patient outcomes.

Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

When it comes to the topic of drug discovery and development, scientists are busy furrowing their lab-goggled brows trying to understand what's real and what's hype when it comes to the power and potential of AI. This *Resonance Test* conversation perfectly dramatizes the situation. In this episode, Emma Eng, VP of Global Data & AI, Development at Novo Nordisk, and Chris Waller, EPAM's VP of Scientific Informatics Consulting and Chief Scientist in Life Sciences, provide a candid view of drug development in the AI era. “We're standing on a revolution,” says Eng, reminding us that “we've done it so many other times” with the birth of the computer and the birth of the internet. It's prudent, she cautions, not to rush to judgement guided by either zealots or skeptics. Waller says, of the articles about AI and leadership in *Harvard Business Review,* one could do “a search and replace ‘AI' with any other technological change that's happened in the last 30 years. It's the same kind of trend and processes and characteristics that you need in your leadership to implement the technology appropriately to get the outcomes that you're looking for.” Which means, for pharma, much uncertainty and much experimentation. “I think experimentation is good,” says Eng, who then adds that we need to always keep track of what is it that we're experimenting on. She says that the word “experimentation” can “sound very fluid” but in fact, “It's a very structured process. You set up some very clear objectives and you either prove or don't prove those objectives.” Waller references the various revolutions (throughput screening, combinational chemistry, data, and analytics revolutions) that pharma has seen and says: “We've all held out hope for each and every one of these revolutions that the drug discovery process is going to be shrunk by 50% and cost half as much. And every time we turn around, it's still 12 to 15 years, $1.5 to $2 billion.” Will AI make the big difference, finally? “Maybe we need to be revolutionized as an industry,” she says. “It can be hard to make much of a difference as long as there are few big players.” Just a few big players, she says, is “the nature of pharma.” Of course, our scientists are measured in their assessments about industry change. After all, as Waller says, the systems involved—the human body, the regulatory environment, the commercial ecosystems—are all “super-complicated.” Eng notes that an important side-effect around the AI hype is corporate interest in data. “Now it's much easier to put that topic on the table saying, ‘If you want to do AI, you need to take care of your data and you need to treat it like an asset.'” Listen on as they test topics such as regional and regulatory challenges in AI adoption, change management, and future tech and long-term impact (watch out for quantum, everyone!). In the end, Eng returns to the idea of revolutions. “You think you want so much change in the beginning which you don't get because it takes time,” says Eng. This makes us underestimate what will happen later. Having such a farseeing mindset is significant, she says, because “these technology shifts will have a large impact on the long term.” Host: Alison Kotin Engineer: Kyp Pilalas Producer: Ken Gordon

Meet Dr. Bo Wen, a staff research scientist, AGI specialist, cloud architect, and tech lead in digital health at IBM. He's joining us to discuss his perspective on the rapid evolution of AI – and what it could mean for the future of human communication… With deep expertise in generative AI, human-AI interaction design, data orchestration, and computational analysis, Dr. Wen is pushing the boundaries of how we understand and apply large language models. His interdisciplinary background blends digital health, cognitive science, computational psychiatry, and physics, offering a rare and powerful lens on emerging AI systems. Since joining IBM in 2016, Dr. Wen has played a key role in the company's Healthcare and Life Sciences division, contributing to innovative projects involving wearables, IoT, and AI-driven health solutions. Prior to IBM, he earned his Ph.D. in Physics from the City University of New York and enjoyed a successful career as an experimental physicist. In this conversation, we explore: How Dr. Wen foresaw the AI breakthrough nearly a decade ago The implications of AGI for communication, reasoning, and human-AI collaboration How large language models work. What AI needs to understand to predict words in sentences. Want to dive deeper into Dr. Wen's work? Learn more here! Episode also available on Apple Podcasts: http://apple.co/30PvU9C

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 1856, after yet another day of disappointing experiments, a chemist named William Henry Perkin was cleaning up his glassware when he made a discovery that would harken a new — and colorful — era of science and industry. Just 18 years old, Perkin was a promising young student in a prestigious lab at the Royal College of Chemistry in London and he was supposed to be figuring out a way to make a chemical compound called quinine. Despite his best efforts, Perkin was coming up empty — or rather — producing a lot of dirty dishes with little to show for it. But he did notice that there was a curious goop in one of his flasks, and it turned a brilliant shade of purple in the wash. Intrigued, Perkin decided to try dyeing a swatch of silk with his serendipitous solution. Although he had failed yet again to produce quinine, Perkin had created the very first synthetic dye and launched a scientific industry that is still bringing new drugs and dyes to market today.Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Österreichische Universitäten und Unternehmen arbeiten an Therapien, die Patient:innen real helfen – doch wie kommen Forschungsergebnisse in die Anwendung? Wie läuft die Entwicklung eines Arzneimittels wirklich ab, welche Hürden gibt es bei IP, Finanzierung und Regulierung – und worauf kommt es in Kooperationen zwischen Uni und Industrie an? Darum geht es in der dritten Folge von „From Science to Business“.Am Round-Table diskutieren:Christine Bandtlow – Vizerektorin für Forschung & Internationales, Medizinische Universität InnsbruckManfred Rieger – Standortleiter und Geschäftsführer des Forschungs- und Entwicklungsbereiches von Takeda in ÖsterreichIm Gespräch wird klar: Der Transferpfad in Life Sciences ist lang und komplex – erfolgreich wird er durch klare IP-Regeln, belastbare Finanzierungsmodelle, regulatorische Sicherheit und Kooperationen auf Augenhöhe."From Science to Business" setzen wir gemeinsam mit unseren Partnern AplusB (Academia plus Business), Austria Wirtschaftsservice (aws), MedLifeLab Innovation Hub (Medizinische Universität Innsbruck), Noctua Science Ventures, JKU - LIT Open Innovation Center (Johannes Kepler Universität Linz), OÖ HightechFonds, Spin-off Austria, Takeda, tecnet equity, The Spinoff Factory (Technische Universität Wien), Universität Innsbruck und WU (Wirtschaftsuniversität Wien) um.

Katie Henry has seen some things. From nonprofit bootstraps to Big Pharma boardrooms, she's been inside the machine—and still believes we can fix it. We go deep on her winding road from folding sweaters at J.Crew to launching a vibrator-based advocacy campaign that accidentally changed the sexual health narrative in breast cancer.Katie doesn't pull punches. She's a born problem solver with zero tolerance for pink fluff and performative empathy. We talk survivor semantics, band camp trauma, nonprofit burnout, and why “Didi” is the grandparent alter ego you never saw coming.She's Murphy Brown with a marimba. Veronica Sawyer in pharma. Carla Tortelli with an oncology Rolodex. And she still calls herself a learner.This is one of the most honest, hilarious, and refreshingly real conversations I've had. Period.RELATED LINKS:Katie Henry on LinkedInKatie Henry on ResearchGateLiving Beyond Breast CancerNational Breast Cancer CoalitionFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Professor Cougar Hall sits down with Greg Hooke, a senior in Public Health and member of the College of Life Sciences Student Belonging Council, to explore what “belonging” really means at BYU—and how simple acts of connection can change campus culture. Greg shares how a Johns Hopkins internship studying bias in long-COVID care opened his eyes to everyday experiences of being unseen, and how that sparked student-led efforts at BYU: first-gen mentoring lunches, a Women in Life Sciences dinner, and hands-on service with Help Me Grow Utah and United Way. He and Dr. Hall unpack the tension between competition and collaboration in tough gateway classes, swap practical ways introverts and extroverts alike can make friends, and celebrate a college-wide bump in belonging (now ~86%). Greg also opens up about recovering from a traumatic brain injury, the faith that grounded him, and his goal to become a neurologist who blends clinical care with public-health principles of inclusion. If you're new to campus—or helping those who are—this episode is equal parts playbook and pep talk. Recorded, Edited & Produced by Christy Gonzalez, Harper Xinyu Zhang, Kailey Hopkins, and Tanya Gale

In today's rapidly evolving business landscape, scaling enterprise sales teams presents unique challenges and opportunities. As the Chief Revenue Officer of Motive, Adam Block brings a wealth of experience in building high-performance sales organizations. In this episode, we explore effective strategies for scaling enterprise sales teams in the AI era.                   Scaling Enterprise Sales: Key Insights ·         Building a robust playbook for enterprise sales success ·         Implementing effective hiring and onboarding processes ·         Leveraging AI and technology to enhance sales efficiency ·         Developing a strong sales culture and team dynamics The Power of People in Scaling Sales One of the core themes Adam emphasizes is the importance of hiring and developing top talent. He outlines: A comprehensive interview process, including panel interviews Assessing candidates' resilience, accountability, and discipline Creating a "farm system" for developing sales talent internally Develop Clear Playbooks Adam outlined three crucial elements of effective sales playbooks: Product knowledge - Understanding what you sell and how it impacts customers Clear expectations - Outlining exactly what's expected in each role Unified approach - A consistent philosophy for engaging prospects Boosting Seller Efficiency and Pipeline Growth Adam provides practical strategies for improving sales performance, including:                          ·         Focusing on pre-hello activities to secure initial conversations ·         Utilizing AI for account research, territory planning, and meeting assessments ·         Balancing technology with human touch in the sales process The Role of AI in Modern Sales While AI is transforming many aspects of sales, Adam cautions against over-reliance: ·         AI tools for enhancing productivity and insights ·         The continued importance of human connection in sales ·         Balancing AI automation with personalized outreach This episode offers a comprehensive look at scaling enterprise sales teams, blending time-tested strategies with cutting-edge AI applications. Whether you're a sales leader looking to grow your team or a sales professional aiming to enhance your skills, you'll find actionable insights to elevate your sales game. Key Moments 00:00:00 - Effective Sales Strategies for Market Contact 00:00:42 - Introduction to Adam Block and Motive 00:04:32 - Adam Block's Guilty Pleasure: 80s Music 00:07:19 - Scaling Enterprise Sales Organizations 00:15:36 - Finding and Assessing Top Sales Talent 00:20:58 - Panel Interview Process for Sales Candidates 00:32:46 - Boosting Seller Efficiency and AI Integration 00:47:50 - Closing Thoughts and Career Opportunities at Motive About Adam Block Adam oversees Motive's global Revenue and Go-To-Market functions, including sales, business development, strategy, operations, sales engineering, and partnerships. Prior to Motive, he served as Vice President over the Public Sector, Healthcare, Manufacturing, High Tech, and Life Sciences teams at Medallia, the leading enterprise experience platform. During his tenure, Medallia went public and was later acquired for $6.4B. Before Medallia, Adam was Vice President, Sales and Marketing for TenMast software (now MRI software) and previously served as Partner and Vice President of Sales at Zeta Marketing, an internet marketing startup. Adam earned his Bachelor of Business Administration (BBA) in Finance and Management from the University of Kentucky. Follow Us On: ·         LinkedIn ·         Twitter ·         YouTube Channel ·         Instagram ·         Facebook Learn More About FlyMSG Features Like: ·         LinkedIn Auto Comment Generator ·         AI Social Media Post Generator ·         Auto Text Expander ·         AI Grammar Checker ·         AI Sales Roleplay and Coaching ·         Paragraph Rewrite with AI ·         Sales Prospecting Training for Individuals ·         FlyMSG Enterprise Sales Prospecting Training Program Install FlyMSG for Free: ·         As a Chrome Extension ·         As an Edge Extension  

In this episode of Tiny Show and Tell Us, a listener on “team wasp” writes in with some interesting info on USDA wasps for pesticide-free pest control and we learn about some wasp versus beetle drama. Then we talk about how our red blood cells use and expel iron, and how a huge percentage of the iron we get is from broken down blood cells.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Ever wonder why EHRs seem stuck in the past—built for billing, patched with add-ons, and painful for clinicians? Oracle Health has taken a different route.In this interview, Seema Verma, EVP and General Manager of Oracle Health and Life Sciences, explains why the company rebuilt its EHR from the ground up. She discusses why old databases can't support modern AI, how Oracle is opening the platform so providers can build and even monetize their own AI agents, and why physicians at beta sites used it with zero training. She also touches on what's next, from clinical trials integrated into care delivery to reducing payer-provider friction.How do you perceive Oracle's new EHR? Drop your thoughts in the comments.

在世界與美國情勢及相應政策皆加劇動盪的年代，身為在美國科學界的學人們是如何因應呢？這次我們邀請了在美國聖路易華盛頓大學基因體與遺傳學系的金聖智教授一起來聊聊我們成長路上直到2025年6月的大事件，以及在大環境的變遷下大家都是怎麼自處的。原來我們一路上也度過了好多動盪的時刻，或許這就是成長路上必須不斷學習的課題吧？ 相關連結 Faculty Spotlight Jin Lab 工作人員 內容製作：雯薇、Angel、Peter 後製：雯薇 文案：雯薇 音樂：雯薇 封面：雯薇 上架：雯薇 宣傳：Angel、雯薇 -- Hosting provided by SoundOn

Vediamoci! Il 24 settembre, alle 18:00 siamo alla Triennale di Milano per un nostro live podcast!

We're excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Viraj Narayanan, CEO at Cornerstone AI. Cornerstone uses AI to clean and standardize healthcare data. Cleaning healthcare data is a non-sexy job that consumes staggering amounts of resources in the industry. When Narayanan […]

Send us a textIn this episode of the Life Science Success Podcast my guest is Josh Yelen, a CPA, MBA, and the Founder & CEO of Function, a strategic financial leadership and bookkeeping services company that supports businesses across various industries, including life sciences. With over two decades of experience in operations, accounting, finance, and sales, Josh is also a co-founder of Venture Forward Capital, where he supports early-stage entrepreneurs in building disruptive companies.00:00 Introduction to Life Science Success Podcast00:40 Join Our Free School Community01:41 Introducing Our Guest: Josh Yelen02:10 Josh Yelen's Professional Journey04:30 The Birth of Venture Forward Capital and Function09:05 Function's Unique Approach to Financial Services14:55 Challenges in Biotech and Pharma20:40 Trends Shaping the Future of Biotech29:19 Firing the Biggest Client and Growing the Business29:46 Innovative Use of AI in Business30:53 Aligning Company Goals with OKRs32:45 The Importance of Focus and Avoiding Distractions36:46 Leadership Advice and Entrepreneurial Challenges39:31 Motivational Videos and Personal Drive45:37 Concerns About AI and the Future of Work50:48 Excitement for the Future and Final Thoughts

On September 18, 2025, and we got to talk with Ricardo Mozzachiodi about what was learned and what we continue to learn about the cellular and molecular basis of memory by studying simple behaviors in a mollusk, Aplysia california, the sea hare. Ricardo filled us in on the original rationale for studying cell biology of learning in this animal, and current findings on the role of neuromodulators in learning.Guest:Ricardo Mozzachiodi, Professor, Department of Life Sciences, Texas A&M University, Corpus Christi. Participating:Alfonso Apicella, Department of Neuroscience, Developmental and Regenerative Biology, UTSAHost:Charles Wilson, Department of Neuroscience, Developmental and Regenerative Biology, UTSAThanks to James Tepper for original music

Back in April, a company called Colossal Biosciences announced that they had brought dire wolves — ancient canines of Game of Thrones fame — back from extinction. The internet went wild. But while some media outlets proclaimed the return of a long-gone species, many scientists shot back on social media that these weren't really dire wolves, they were just genetically engineered grey wolves. Suddenly everybody had an opinion on what de-extinction is, what it is not, and whether or not we should be doing things like this in the first place. In this episode, we talk to scientists who have been working in this area for a while, and they not only share their thoughts on these wolves — they completely change our understanding of the term “de-extinction.”Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Morrison Foerster partners Kate Driscoll and Nate Mendell, both former federal prosecutors and members of the firm's Investigations + White Collar Defense Group, hosted the eleventh episode of When Your Life Sciences Are on the Line, where leading practitioners and thought leaders share the insights and advice needed to manage business and legal risk in the life sciences sector.

In this episode of EisnerAmper's Private Equity Dealbook, Elana Margulies-Snyderman, Director, Publications, speaks with Robert Esposito, Managing Director in the firm's Transaction Advisory Services Group. Bob shares his outlook for dealmaking in the life sciences industry, including the opportunities, challenges and due diligence considerations. He also discusses what private equity managers look for in the buy-side process to better ensure that both a mutually beneficial and efficient transaction can be consummated in today's economic and transaction market environment. The conversation dives deep into life sciences M&A, private equity dealmaking, and healthcare investment strategies. Whether you're an investor, entrepreneur, or advisor, you'll gain insights into how deals are structured, what risks matter most, and where the biggest opportunities lie in 2025.

In der aktuellen Folge sprechen Alois Krtil und Oliver Rößling mit Prof. Hauke Heekeren, Arzt, Neurowissenschaftler und seit 2022 Präsident der Universität Hamburg. Ein Gespräch über Hamburgs wissenschaftlichen Aufbruch, die Rolle von Vernetzung und Transfer – und darüber, wie Künstliche Intelligenz Lehre, Forschung und Verwaltung verändert.Hamburg hat in den vergangenen Jahren deutlich aufgeholt. Die Universität Hamburg konnte ihre vier Exzellenzcluster erfolgreich in die nächste Förderperiode bringen – von Astrophysik und Photon Science bis Klima und Schriftartefakte. Zusätzlich gewann die TU Hamburg mit BlueMat ein weiteres Cluster im Bereich Materialforschung. Zusammen ergibt das fünf Exzellenzcluster in der Metropolregion und damit ein starkes Signal für den Standort.Heekeren betont besonders die Vernetzung als Standortvorteil: Hamburg sei groß genug für Spitzenforschung, aber klein genug, um alle relevanten Akteure an einen Tisch zu bekommen. Beispielhaft steht dafür PIER, die Partnerschaft von Universität Hamburg und DESY, und ihr Ausbau zu PIER PLUS, wo 23 Hochschulen und Forschungseinrichtungen gemeinsam Strategien für Forschung, Transfer und Karrierewege entwickeln.Beim Thema Transfer verfolgt die Universität einen breiten Ansatz: von Politikberatung und Bürgerdialog bis zu Start-ups und Ausgründungen. Ein aktuelles Leuchtturmprojekt ist die Initiative Impossible Founders, die im Rahmen der bundesweiten „Startup Factories“ gefördert wird. Mehr als 50 Millionen Euro von Bund, Stiftungen und Unternehmen fließen in eine Gründungsfabrik für Deep-Tech-Spin-offs, die ab Herbst 2025 operativ startet. Mit Arik Willner wurde ein erfahrener Transfermanager als CEO gewonnen.Ein weiteres Zukunftsprojekt ist die Science City Bahrenfeld: ein kompletter Stadtteil, in dem Leben, Forschen, Studieren und Gründen zusammengeführt werden. Rund um DESY, eines der führenden Forschungszentren für Photon- und Teilchenphysik, entsteht Infrastruktur, die von Quantenforschung bis zu Life Sciences reicht – inklusive gemeinsamer Institute der Universität.Ein zentrales Thema ist die Künstliche Intelligenz. Die Universität Hamburg hat früh eine eigene, datenschutzkonforme Variante von ChatGPT eingeführt. Heekeren plädiert für einen reflektierten Einsatz: KI könne Prozesse beschleunigen und Ideen anstoßen, dürfe aber wissenschaftliche Urheberschaft und kritisches Denken nicht ersetzen. Als Beispiel nennt er die automatisierte Prüfung internationaler Bewerbungsunterlagen – eine Lösung, die aus Kooperationen mit der Hamburger Hafenwirtschaft hervorging.Im Gespräch wird deutlich, dass Europa mit seinen Werten eine besondere Rolle spielen kann. Während in den USA oder China Technologien oft rein marktorientiert oder staatlich gesteuert vorangetrieben werden, setzt Heekeren auf Wissenschaftsfreiheit, kostenfreie Bildung und Interdisziplinarität als Standortvorteile. Gerade eine Volluniversität, die Natur- und Ingenieurwissenschaften mit Geistes-, Rechts- und Sozialwissenschaften verbindet, sei unverzichtbar, um Fragen nach Ethik, Recht und gesellschaftlicher Verantwortung von KI zu beantworten.Zum Schluss formuliert Heekeren drei zentrale Aufgaben für Hamburgs Wissenschaftsstandort:Talente gewinnen und halten – von jungen Forschenden bis zu Spitzenkräften in Informatik und KI.Forschungstechnische Infrastruktur ausbauen, insbesondere große GPU-Cluster.Transfer und Karrierewege beschleunigen, um wissenschaftliche Erkenntnisse schneller in die Anwendung zu bringen.Die Folge zeigt Hamburg als Standort mit klarer Richtung: Fünf Exzellenzcluster, enge Vernetzung, eine entstehende Science City und eine Universität, die KI nicht nur nutzt, sondern gestaltet. Heekerens Botschaft: Vernetzung, Verantwortung, Geschwindigkeit – wenn diese Faktoren zusammenkommen, wird aus Forschung gesellschaftlich spürbarer Fortschritt.

"Every community has different values, and every community should have different choices. And that's why local food is so important so that local communities and local farmers can decide what's most important to them and how they want to connect the people who grow our food with the people who are seeking nourishment." —Andy Naja-Riese "The health of our Farmers Market is really dependent upon the health of our farmers." —Tanner Keys   Wonder why local food sometimes costs more, or if it's really worth the effort to shop there? The real story behind farmers' markets is more complicated—and more important—than you might think. Andy Naja-Riese, CEO of the Agricultural Institute of Marin, and Tanner Keys, Cooperative Agreement Manager for the Islands of Remote Areas Regional Food Business Center, have spent years on the front lines of food access. Their work in California and Hawaii gives them a unique view on what it takes to make local food affordable, how certification and regulations shape what you see at the market, and why these markets matter for everyone. Listen in for honest talk about food prices, local farming, organic rules, food as medicine, and how farmers' markets are working to make healthy food available to all. You'll get practical insights, real solutions, and a fresh look at what's possible in your own community. Meet Andy: Andy Naja-Riese brings 17 years of experience in community food systems, public health, and food equity programs & policy. As Chief Executive Officer, he leads AIM's major programs, partnerships, strategic planning, advocacy, and fundraising, including a capital campaign for AIM's Center for Food and Agriculture in collaboration with AIM's Board of Directors. Andy joined AIM in 2018 after spending 10 years working for the Federal government, including the U.S. Department of Agriculture's Food and Nutrition Service.  Andy is currently the Co-Chair of the Marin County Healthy Eating Active Living (HEAL) Collaborative, serves on the Steering Committees of the Marin Carbon Project and Marin Community Health Improvement Plan, sits on the National Farm to School Network's Advisory Board, and represents AIM on the California Food and Farming Network & Food and Farm Resilience Coalition. He received the 2022 CVNL Heart of Marin Award for Excellence in Leadership and the 2023 Farmers Market Champion of the Year award from CAFF. He earned his master's degree from the T.H. Chan Harvard School of Public Health and his bachelor's degree from Cornell University's College of Agriculture and Life Sciences.  He lives with his husband and dog in Sonoma, where he enjoys backyard gardening, cooking farmers market hauls, eating bagels, and enjoying Northern California's natural beauty Website Facebook X Instagram LinkedIn YouTube   Meet Tanner: Tanner Keys grew up in an agricultural community & lifestyle that has instilled a passion for food & land. He has served in various roles with the Hawaiʻi Good Food Alliance (HGFA) beginning in 2022, helping the organization in its beginning years and later leading a project of HGFA, the Hawaiʻi Farmers Market Association. Before that, he served as the Team Leader to the FoodCorps Inc., an AmeriCorps program, from 2019 to 2021. Tanner has a B.S. in Business Administration from the University of Oregon, and it was his service in the Peace Corps (Timor-Leste ʻ16-ʻ18) that led him back to the path of supporting agriculture & food security. LinkedIn Connect with Hawai'i Good Food Alliance Website Instagram Facebook   Connect with NextGen Purpose: Website Facebook Instagram LinkedIn YouTube   Episode Highlights: 01:16 Geography and Food Access: How Location Changes Everything 06:13 Comparing Coasts: East vs West Market Experiences  10:38 Organic vs Certified— What “Certified” Really Means  16:53 Hawaii and California's Diversity  23:40 Making Markets Accessible  27:55 Permanent Market Dreams: Building for the Future  33:57 Are Farmers' Markets Expensive? The Real Price of Local Food   Resources: Podcast S5 Ep 27: AIM— Preserving the Farmer's Market for Everyone with Andy Naja-Riese Part 2S7 Ep1: Boosting a Healthy, Accessible Local Farm-to-Table Revolution with Andy Naja-Riese Part 2

Sophie Sargent walked into the studio already owning the mic. A pandemic-era media rebel raised in New Hampshire, trained in Homeland Security (yep), and shaped by rejection, she's built a career out of DM'ing her way into rooms and then owning them. At 25, she's juggling chronic illness, chronic overachievement, and a generation that gets dismissed before it even speaks.We talk Lyme disease, Lyme denial, and the healthcare gaslighting that comes when you “look fine” but your body says otherwise. We dive into rejection as a career accelerant, mental health as content porn, and what it means to chase purpose without sacrificing identity. Sophie's a former morning radio host, country music interviewer, and Boston-based creator with a real voice—and she uses it.No fake podcast voice. No daddy-daughter moment. Just two loudmouths from different planets figuring out what it means to be seen, believed, and taken seriously in a system designed to do the opposite.Spoiler: She's smarter than I was at 25. And she'll probably be your boss someday.RELATED LINKSSophie on InstagramSophie on YouTubeSophie on LinkedInMedium article: “Redefining Rejection”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when you hand a mic to the most extroverted, uncensored Gen Z career coach in New York? You get Olivia Battinelli—adjunct professor, student advisor, mentor, speaker, and unfiltered truth-teller on everything from invisible illness to resume crimes.We talked about growing up Jewish-Italian in Westchester, surviving the Big Four's corporate Kool-Aid, and quitting a job after 7 months because the shower goals weren't working out. She runs NYU Steinhardt's internship program by day, roasts Takis and “rate my professor” trolls by night, and somehow makes room for maple syrup takes, career coaching, and a boyfriend named Dom who sounds like a supporting character from The Sopranos.She teaches kids how to talk to humans. She's allergic to BS. And she might be the most Alexis Rose-meets-Maeve Wiley-mashup ever dropped into your feed. Welcome to her first podcast interview. It's pure gold.RELATED LINKS:Olivia Battinelli on LinkedInOlivia's Liv It Up Coaching WebsiteOlivia on InstagramNYU Steinhardt Faculty PageFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Meg speaks to Ilya Burkov, the Global Head of Healthcare & Lifesciences Growth at Nebius AI.Nebius AI's goal is simple: to provide the cloud infrastructure that will be the groundwork of the AI revolution we can all see happening in front of us. Nebius' suite of tools helps life science companies gather data and then train, fine-tune and launch their AI models into the world.Ilya's role is to oversee and drive the adoption of this cloud AI technology within the life science and healthcare sectors, placing him at the cutting edge of this next wave of industry change. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

In this episode of the Econ Dev Show, Dane Carlson sits down with Kathleen Coviello, Chief Economic Transformation Officer at the New Jersey Economic Development Authority, to explore how New Jersey is reshaping its economic future. Kathleen discusses the state's targeted approach to building industries where it has a competitive edge—from film and digital media to life sciences, clean energy, and AI. She shares insights into innovative initiatives like film-ready certified towns, programs that turn company losses into cash, and the ambitious Evergreen Fund designed to attract venture capital and corporate engagement. Along the way, Kathleen highlights both the opportunities and challenges facing New Jersey, including housing affordability and talent retention, while also offering a candid look at her own journey from venture banking to two decades in public service. Like this show? Please leave us a review here (https://econdevshow.com/rate-this-podcast/) — even one sentence helps! Special Guest: Kathleen Coviello.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Kaan-Fabian Kekec, Partner in Healthcare and Life Sciences at Simon-Kucher. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kaan, covering: Being on the sunny side of consulting, and helping clients unlock growth. What makes a key strategic partnership both from a CDMO, and a sponsor perspective. The taboo subject of pricing and how it can be used to help unlock commercial positioning, and excellence. Common mistakes in BD teams, and the importance of value positioning. The hottest segments in the market right now, and some of the competitive drivers in today's market. Kaan leads the firm's Healthcare B2B and Pharma Services business globally, encompassing CDMOs, CROs, bioprocessing solutions, drug delivery, packaging, and more. He specializes in delivering end-to-end commercial strategies for CDMOs, advising on growth initiatives and supporting clients throughout the entire lead-to-deal process—from marketing and sales to proposal management and deal optimization. Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.  Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Many supplements claim to “boost” your immune system. Now, we all want to avoid getting sick during the winter months, but do any of these products really work? And is trying to “boost” your immune system even a good idea? Jonathan speaks with Professor Daniel M. Davis, MBE — a leading expert on immunology and Head of Life Sciences at Imperial College London. Daniel has published 145 scientific papers, authored four best-selling science books, and spent 25 years researching how our immune system works. He even helped discover the immune synapse, a breakthrough that changed our understanding of immunity. Daniel explains how your immune system really works, why it's connected to mental health, and how it can even detect cancer cells. He also clears up common myths and shares what genuinely helps keep your immune system strong through the winter months — and what won't make a difference. By the end of the episode, you'll know the practical, science-backed steps you can take to reduce your risk of colds and flu this winter without wasting money on products that don't deliver. Unwrap the truth about your food

In this episode, Seema Verma, EVP and GM of Oracle Health and Life Sciences, discusses Oracle's vision for transforming healthcare through AI, interoperability, and next-generation EHR technology. She shares insights on reducing administrative costs, advancing clinical research, improving prior authorization, and strengthening cybersecurity to create a more efficient and patient-centered system.This episode is sponsored by Oracle.

In this episode of Tiny Show and Tell Us, we talk about cute woolly mammoth mice and debate whether research to bring back extinct species (or their genes) is ethical or a good use of money and time. Then we discuss the best way to remove microplastics from water. We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Looking for the secret sauce behind building a top-tier recruiting agency in a hyper-competitive market? Want to combine heart-driven recruiting with razor-sharp business strategy? In this must-listen episode, Benjamin Mena sits down with Cari Kraft—legendary leader and top biller at Jacobs Management Group—to reveal how niching down and leading with integrity can skyrocket your recruiting business.  

Join us this week for The Tech Leaders Podcast, where Gareth sits down with Chris Moore, European President at Veeva Systems. Chris talks about the impact AI will have on software development and data security, how technology has transformed the life sciences industry, and the long-term implications of Covid on drug development.On this episode, Chris and Gareth discuss how Chris helped make Veeva Europe more European, the importance of understanding the opportunities and threats associated with new technologies, and why the Y2K bug was a beautiful anti-climax.Timestamps:ICI, Kinesis and PWC (3:40)IBM, EY and living abroad (10:28)Making Veeva Europe more European (17:30)The impact of Covid on drug development (29:05)The evolution of the CIO (33:00)AI: Hopes, fears and the impact on software development and pharma (36:33)Advice for 21-year-old Chris (51:46)https://www.bedigitaluk.com/

This episode is sponsored by Invivyd, Inc.Marc Elia is a biotech investor, the Chairman of the Board at Invivyd, and a Long COVID patient who decided to challenge the system while still stuck inside it. He's not here for corporate platitudes, regulatory shoulder shrugs, or vaccine-era gaslighting. This is not a conversation about politics, but it's about power and choice and the right to receive care and treatment no matter your condition.In this episode, we cover everything from broken clinical pathways to meme coins and the eternal shame of being old enough to remember Eastern Airlines. Marc talks about what it means to build tools instead of just complaining, what Long COVID has done to his body and his patience, and why the illusion of “choice” in healthcare is a luxury most patients don't have.This conversation doesn't ask for empathy. It demands it.RELATED LINKSMarc Elia on LinkedInInvivyd Company SiteMarc's Bio at InvivydFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textIn this episode, we will interview Dr. Thomas Cavaliere, the current Dean of the Rowan Virtua School of Osteopathic Medicine. Dr. Cavaliere graduated from the Des Moines University College of Osteopathic Medicine, following which he completed an internal medicine residency at Thomas Jefferson University Hospital. Under his leadership, the Rowan Virtua School of Osteopathic Medicine has been named one of the best medical schools in the country for primary care and geriatric medical education. Dr. Cavalierey has also recently been selected to serve as the inaugural Senior Vice Provost of the Virtua Health College of Medicine and Life Sciences, as well as the Chief Academic Officer for the Virtua Health System. It is an honor to interview such an accomplished physician, and we believe his perspectives are valuable for everyone from pre-medical students to attending physicians. Dr. Cavaliere will discuss the advantages of pursuing a career in academic medicine, emphasizing the opportunity to combine clinical practice with teaching and research, and the fulfillment of caring for patients while training the next generation of physicians. We know you will love this episode.

As clinical research becomes increasingly digital, the legal and compliance landscape is shifting. Hal Porter, Director of Consulting Services, Clearwater, speaks with Dianne Bourque, Partner, Holland & Knight LLP, about the legal, regulatory, and ethical considerations when clinical trial data is compromised. They discuss issues related to regulatory frameworks and legal obligations, risk exposure and liability, impacts of a breach that go beyond privacy, cross border data and transfer risks, and mitigating the risk and fallout of data breaches in clinical trials. Sponsored by Clearwater.Watch this episode: https://youtu.be/XwtZXXGmLx4Learn more about Clearwater: https://clearwatersecurity.com/ Essential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Adam Siebert, Managing Director and Partner at L.E.K. Consulting. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adam, covering: Adam's journey from academic to commercial, and what helped him transition into 'life science enablers". How pandemic demand has left our sector with a huge over capacity issue and market imbalance. Some positive signals for the second half of 2025 after a period of geopolitical chaos, and a bumpy rollercoaster. Even thought biotech funding has largely returned... how decreasing clinical trials, a shifting of therapeutic focus, and the concentration of investments on fewer, higher value deals is impacting pharma services. The value of building a reputation in one in-demand modality area before extending into other modalities. And why the CDMO is at an inflexion point... Adam is a Managing Director and Partner in L.E.K. Consulting's New York office and a member of the Life Sciences practice. He has been with L.E.K. for over eight years, and has experience across diagnostics and research tools, bioprocessing and pharma services, and emerging, mid-cap and large pharma. Adam has helped a number of clients in the life sciences industry with growth strategy, life cycle management, portfolio optimization and M&A projects. Adam holds a Bachelor of Science from Boston College and a Ph.D. from the Perelman School of Medicine at the University of Pennsylvania.    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.

After years of carrying the weight of lead, Shannon and Cooper find a path out from under the darkness and into the sunlight.LEAD: how this story ends is up to us is an audio docudrama series that tells the true story of one child, his mysterious lead poisoning, and his mother's unwavering fight to keep him safe. A true story written by Shannon Burkett. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.Lead was produced by Shannon Burkett. Co-produced by Jenny Maguire. Featuring Amy Acker, Tom Butler, Dennis T. Carnegie, James Carpinello, Geneva Carr, Dann Fink, Alice Kris, Adriane Lenox, Katie O'Sullivan, Greg Pirenti, Armando Riesco, Shirley Rumierk, Thom Sesma, and Lana Young. Music by Peter Salett. “Joy In Resistance” written by Abena Koomson-Davis and performed by Resistance Revival Chorus. Casting by Alaine Alldaffer and Lisa Donadio. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Sounds of Science, learn how the Retrogenix® platform is reshaping drug development by identifying off-target risks earlier, reducing animal use, and gaining traction with regulators—now as part of the FDA's ISTAND pilot program. Guests Nick Brown and Mark Aspinall-O'Dea from Charles River Discovery Services share real-world insights on their role in advancing NAMs and supporting safer, faster therapeutic development.Show Notes Maximize Safer, Targeted Biologic Development with Smarter NAMs-Based Off-Target Screening Paving the Way for Enhanced Drug Development A Status Report on Cell-Based Protein Arrays Retrogenix® Human Protein Library Retrogenix®: The Screen Door of Drug Development Retrogenix® CAR Specificity Testing Charles River Launched New Retrogenix Non-Human Protein Library 

This week, we went to the doctor. Oz speaks with Dr. Matthew Lungren, the Chief Scientific Officer for Microsoft Health & Life Sciences, who co-authored a study showing that AI diagnosed complex medical cases four times faster than human doctors. Dr. Lungren walked us through how multiple AI agents worked together to generate their diagnoses, what that means for the future of medicine—and how human doctors and AI could collaborate to build a more democratized healthcare system.See omnystudio.com/listener for privacy information.

The deficits from the lead poisoning continue to intensify, Shannon channels her anger and grief into holding the people who hurt her son responsible.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.EP4 features Eboni Booth, Sasha Eden, Kevin Kane, April Matthis, Alysia Reiner, and Mandy Siegfried. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jim talks with Lawrence Cahoone about the ideas in his book The Orders of Nature: An Introduction to the Philosophy of Complex Systems for the Life Sciences. They discuss how Cahoone's naturalist philosophy bridges multiple philosophical domains, his distinctive use of emergence theory borrowed from William Wimsatt, the concept of "no simples" in objective relativism, the role of Prigogine in emergence theory, Cahoone's self-taught approach to understanding physics and science, fallibilist and local metaphysics, Columbian naturalism and its rejection of the supernatural, the relationship between objects and their contexts, scientific explanations of relativity and quantum mechanics, and much more. Episode Transcript The Orders of Nature: An Introduction to the Philosophy of Complex Systems for the Life Sciences, by Lawrence Cahoone The Emergence of Value: Human Norms in a Natural World, by Lawrence Cahoone The Feynman Lectures on Physics, by Richard Feynman Lawrence Cahoone graduated with a Ph.D. in Philosophy at Stony Brook University in 1985. Cahoone's areas of specialization are American Philosophy, Continental Philosophy, Social and Political Philosophy, Philosophy of Culture, Metaphysics and Natural Science and Modernism and Postmodernism. Since 2000, Cahoone has taught at Holy Cross and is now currently an Emeritus Professor of Philosophy at Holy Cross. He has also written and published seven books in his career, including The Emergence of Value, The Orders of Nature, and Cultural Revolutions.

The effects of the neurotoxin are taking their toll on Cooper as Shannon desperately tries to navigate the severity of their new reality.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.E43 features Jenny Maguire, JD Mollison, Laith Nakli, Deirdre O'Connell, Carolyn Baeumler, Zach Shaffer, and Monique Woodley. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Medicine stands at the threshold of a new era, where artificial intelligence and systems biology are working hand in hand to make care more personal, predictive, and precise than ever before. AI is already improving diagnostic accuracy, automating administrative tasks, and uncovering patterns in data—like retinal scans or genomics—that humans often miss. Rather than replacing doctors, AI enhances their ability to deliver more informed, precise, and efficient care. At the same time, individuals are gaining tools—from at-home diagnostics to wearable biosensors—that empower them to track and optimize their own health. This shift marks a move from reactive, disease-centered care to a proactive, data-driven model of scientific wellness. In this episode, I talk with Dr. Eric Topol, Dr. Nathan Price, Dr. Leroy Hood, Dr. Vijay Pande, and Daisy Wolf about how artificial intelligence, personalized data, and wearable technology are converging to radically transform medicine. Dr. Eric Topol is Executive Vice President of Scripps Research and founder/director of its Translational Institute, recognized as one of the top 10 most cited researchers in medicine with over 1,300 publications. A cardiologist and author of several bestselling books on the future of medicine, he leads major NIH grants in precision medicine and shares cutting-edge biomedical insights through his Ground Truths newsletter and podcast. Dr. Nathan Price is Chief Scientific Officer at Thorne HealthTech, author of The Age of Scientific Wellness, and a National Academy of Medicine Emerging Leader. He also serves on the Board on Life Sciences for the National Academies and is Affiliate Faculty in Bioengineering and Computer Science at the University of Washington. Dr. Leroy Hood is CEO and founder of Phenome Health, leading the Human Phenome Initiative to sequence and track the health of one million people over 10 years. A pioneer in systems biology and co-founder of 17 biotech companies, he is a recipient of the Lasker Prize, Kyoto Prize, and National Medal of Science. Dr. Vijay Pande is a General Partner at Andreessen Horowitz and founder of a16z Bio + Health, managing over $3 billion in life sciences and healthcare investments at the intersection of biology and AI. An Adjunct Professor at Stanford, he is known for his work in computational science, earning honors like the DeLano Prize and a Guinness World Record for Folding@Home. Daisy Wolf is an investing partner at Andreessen Horowitz, specializing in healthcare AI, consumer health, and healthcare-fintech innovation. She previously worked at Meta and in various startups, holds a JD from Yale Law, an MBA from Stanford, and a BA from Yale, and is based in New York City. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN10 to save 10%. Full-length episodes can be found here: Can AI Fix Our Health and Our Healthcare System? The Next Revolution In Medicine: Scientific Wellness, AI And Disease Reversal The Future of Healthcare: The Role of AI and Technology